Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an update.
Rhythm Biosciences Ltd. announced a change in the director’s interest, with Sue MacLeman acquiring 450,000 loan funded shares and 450,000 unlisted options, while disposing of 200,000 unlisted options. This change, approved by shareholders at the Annual General Meeting, reflects a strategic adjustment in the company’s governance and may impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. operates in the biotechnology industry, focusing on the development and commercialization of medical diagnostics. The company is known for its innovative products aimed at improving early detection and treatment of diseases, with a particular emphasis on cancer diagnostics.
Average Trading Volume: 343,535
Technical Sentiment Signal: Buy
Current Market Cap: A$28.99M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.